Poland · Delayed Price · Currency is PLN MedApp Statistics
Total Valuation
MedApp has a market cap or net worth of PLN 42.77 million. The enterprise value is 46.25 million.
| Market Cap | 42.77M |
| Enterprise Value | 46.25M |
Important Dates
The last earnings date was Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedApp has 250.13 million shares outstanding.
| Current Share Class | 250.13M |
| Shares Outstanding | 250.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 120.53M |
Valuation Ratios
The trailing PE ratio is 59.09.
| PE Ratio | 59.09 |
| Forward PE | n/a |
| PS Ratio | 6.32 |
| PB Ratio | 2.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 45.89 |
| P/OCF Ratio | 15.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.06, with an EV/FCF ratio of 49.63.
| EV / Earnings | 63.89 |
| EV / Sales | 6.83 |
| EV / EBITDA | 21.06 |
| EV / EBIT | 29.88 |
| EV / FCF | 49.63 |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of 0.09.
| Current Ratio | 0.32 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.88 |
| Interest Coverage | 2.37 |
Financial Efficiency
Return on equity (ROE) is 3.64% and return on invested capital (ROIC) is 6.20%.
| Return on Equity (ROE) | 3.64% |
| Return on Assets (ROA) | 2.63% |
| Return on Invested Capital (ROIC) | 6.20% |
| Return on Capital Employed (ROCE) | 7.86% |
| Weighted Average Cost of Capital (WACC) | 11.26% |
| Revenue Per Employee | 451,400 |
| Profits Per Employee | 48,267 |
| Employee Count | 15 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MedApp has paid 48,000 in taxes.
| Income Tax | 48,000 |
| Effective Tax Rate | 5.31% |
Stock Price Statistics
The stock price has increased by +6.15% in the last 52 weeks. The beta is 1.10, so MedApp's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +6.15% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 35.67 |
| Average Volume (20 Days) | 20,512 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedApp had revenue of PLN 6.77 million and earned 724,000 in profits. Earnings per share was 0.00.
| Revenue | 6.77M |
| Gross Profit | 4.38M |
| Operating Income | 1.55M |
| Pretax Income | 904,000 |
| Net Income | 724,000 |
| EBITDA | 2.20M |
| EBIT | 1.55M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 1.18 million in cash and 1.75 million in debt, with a net cash position of -576,000 or -0.00 per share.
| Cash & Cash Equivalents | 1.18M |
| Total Debt | 1.75M |
| Net Cash | -576,000 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 19.50M |
| Book Value Per Share | 0.07 |
| Working Capital | -9.46M |
Cash Flow
In the last 12 months, operating cash flow was 2.83 million and capital expenditures -1.90 million, giving a free cash flow of 932,000.
| Operating Cash Flow | 2.83M |
| Capital Expenditures | -1.90M |
| Depreciation & Amortization | 648,000 |
| Net Borrowing | -191,000 |
| Free Cash Flow | 932,000 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 64.61%, with operating and profit margins of 22.86% and 10.69%.
| Gross Margin | 64.61% |
| Operating Margin | 22.86% |
| Pretax Margin | 13.35% |
| Profit Margin | 10.69% |
| EBITDA Margin | 32.43% |
| EBIT Margin | 22.86% |
| FCF Margin | 13.76% |
Dividends & Yields
MedApp does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 1.69% |
| FCF Yield | 2.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedApp has an Altman Z-Score of 1.5 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.5 |
| Piotroski F-Score | 6 |